News/Recently@Retina

Recently@Retina Newsletter September 2023

September 26, 2023

Recently@Retina

September 2023

The mission of the Retina Foundation of the Southwest is to prevent vision loss and restore sight through innovative research and treatment for pediatric eye conditions, inherited eye diseases, and age-related macular degeneration.

— LATEST NEWS & EVENTS —

November 2023 Recently At Retina Newsletter Img 02

Dr. Karl Csaky a

Finalist for D CEO

2023 Excellence

in Healthcare

Awards

Outstanding

Healthcare

Innovator

September 2023 Recently At Retina Newsletter Img 02The Retina Foundation is proud to share that CEO and Chief Medical Officer Dr. Karl Csaky has been named as a finalist for Outstanding Healthcare Innovator for D CEO’s 2023 Excellence in Healthcare Awards. As a vitreoretinal specialist and expert in age-related macular degeneration (AMD), Dr. Csaky leads the Retina Foundation’s mission to provide innovative and patient-focused solutions in less time than traditional research institutions to preserve and restore vision. Dr. Csaky is focused on cutting-edge research to make breakthroughs and discover personalized treatment solutions through gene therapy, state-of-the-art stem cell research and clinical studies for numerous novel therapies. Please join us in congratulating Dr. Csaky on this recognition!

D CEO: Finalists Announced: D CEO’s 2023 Excellence in Healthcare Awards – D Magazine

Dallas Innovates: 3 North Texas Innovators in the Spotlight as D CEO Healthcare Award Finalists » Dallas Innovates

 

Thank You for Making NTxSeptember 2023 Recently At Retina Newsletter Img 03

Giving Day a Success!

We raised over $50,000

A little goes a long way when North

Texans give all at once.

www.NorthTexasGivingDay.org/organization/Retina- Foundation-Of-The-Southwest

Focus on Researchers@Retina

September 2023 Recently At Retina Newsletter Img 04Eric Vasquez joined the Molecular Ophthalmology laboratory at the Retina Foundation as a Clinical Research Coordinator in January 2023. A native Tejano of Mexican descent, he was born and raised in a small town in northeast Texas.

Eric is a first-generation student/college graduate earning his degrees from the University of Texas at Austin in Biochemistry and Psychology in 2021. Throughout his undergrad, he discovered an interest in degenerative diseases and made Alzheimer’s disease the topic for many of his research essays. At the same time, his father had been diagnosed with early-onset Alzheimer’s and eventually passed away in 2020. Eric states his father was one of his biggest motivators for working in research to help find cures for debilitating diseases such as Alzheimer’s and Age-Related Macular Degeneration. Eric continues his work coordinating studies and cares deeply for his research participants.

Eye on the Cure Podcast Episode 53: David Birch, PhD

September 2023 Recently At Retina Newsletter Img 05David G. Birch, PhD talks to Foundation Fighting Blindness Eye On the Cure podcast host, Ben Shaberman about his productive and impactful 40-plus-year career as a retinal disease researcher and clinical trial investigator. Dr. Birch also discusses the challenges and opportunities for advancing more therapies through trials and getting those therapies out to the people who need them.

https://soundcloud.com/fndfightingblindness/eye-on-the-cure-podcastepisode-53-david-birch-phd

September 2023 Recently At Retina Newsletter Img 05

Enjoy an artistic and unique evening.

A collection of art and apparel by Kathryn Iklé will be on display and for sale, with a percentage of all sales donated to The Retina Foundation to aid in the fight against blindness.

https://www.kathrynikle.com/artexhibit2023.html

September 2023 Recently At Retina Newsletter Img 06

Recent Clinical Trials @ Retina

A Phase 1 Study to Evaluate the Safety and Tolerability of a New Therapeutic for Retinal Dystrophy

September 2023 Recently At Retina Newsletter Img 07Rose-Silverthorne Laboratory

ClinicalTrials.gov ID: NCT05902962

A study to evaluate the safety and tolerability of IV-administered VP-001 in participants with confirmed PRPF31 mutation-associated Retinal Dystrophy.

A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry AMD

September 2023 Recently At Retina Newsletter Img 08Molecular Ophthalmology Laboratory

ClinicalTrials.gov ID: NCT06018558

A study to evaluate a sterile ophthalmic suspension for subretinal injection. The product, a modifier gene therapy platform, is a new way of addressing a genetic disease arising through a multitude of genetic mutations in various genes.

Please help the Retina Foundation continue ​leading research and saving sight.

 

 

Recently@Retina Newsletter September 2023

Related Articles

Recently@Retina Newsletter January 2024 Introducing the Vision and Neurodevelopment Laboratory Retina Foundation is Major Center for Next Phase of Gene Therapy for X-Linked Retinitis Pigmentosa: SKYLINE Retina foundation showcases breakthroughs for treatment of age-related macular degeneration during eye on innovation conversation series Healthier Eyesight through Smarter Eating is Proven Research
Mailicon
Get the Latest Updates

Sign up to receive emails from Retina Foundation that will keep you up-to-date on our research and events.

  • This field is for validation purposes and should be left unchanged.
Contact Us

Contact Us

  • This field is for validation purposes and should be left unchanged.
x

Please check all that apply:

How did you learn about the
Retina Foundation?

  • Please check all that apply:
  • This field is for validation purposes and should be left unchanged.
Contact Us

Request an Appointment

Please complete this form if you are interested in speaking to a member of our team about your AMD.

all fields required

DOWNLOAD Printable Form